1-<3-propyl>-4-<(4-chlorophenyl)amino>-4-piperidinecarboxamide | 97861-28-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-<3-propyl>-4-<(4-chlorophenyl)amino>-4-piperidinecarboxamide
• 英文别名: 4-(4-chloroanilino)-1-[3-(4-fluoro-N-(4-fluorophenyl)anilino)propyl]piperidine-4-carboxamide
• CAS: 97861-28-4
• 化学式: C₂₇H₂₉ClF₂N₄O
• 分子量: 499.003
• InChiKey: XXYGJIKMVDXQOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.58
• 重原子数：
  35.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-<3-propyl>-4-<(4-chlorophenyl)amino>-4-piperidinecarboxamide 生成 8-<3-propyl>-1-(4-chlorophenyl)-1,3,8-triazaspiro<4.5>dec-2-en-4-one
  参考文献：
  名称：

  WISE, L. D.;PATTISON, I. C.;BUTLER, D. E.;DEWALD, H. A.;LEWIS, E. P.;LOBB+, J. MED. CHEM., 1985, 28, N 12, 1811-1817

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氧代哌啶酮盐酸盐 在 硫酸 、 sodium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 46.5h， 生成 1-<3-propyl>-4-<(4-chlorophenyl)amino>-4-piperidinecarboxamide
  参考文献：
  名称：

  Examination of a series of 8-[3-[bis(4-fluorophenyl)amino]propyl]-1-aryl-1,3,8-triazaspiro[4.5]decan-4-ones as potential antipsychotic agents

  摘要：

  8-[3-[Bis(4-fluorophenyl)amino]propyl]-1-phenyl-1,3,8- triazaspiro[4.5]decan-4-one (3) and related compounds have been shown to have antipsychotic profiles in biochemical and behavioral pharmacological test models. The dose of 3 necessary to produce catalepsy in rats is much greater than that required for activity in behavioral tests predictive of antipsychotic efficacy, for example the suppression of high base line medial forebrain bundle self-stimulation in rats. This suggests that 3 would have a reduced propensity for neurological side effects. The effects of substitution on the 1-phenyl moiety and on the N-3 nitrogen atom of the triazaspirodecanone portion of 3 were examined. Results from this study suggest that behavioral activity is sensitive to substituents on the 1-phenyl moiety while substituents on the N-3 nitrogen are more generally tolerated. In both rats and squirrel monkeys compound 3 was found to have a similar separation between doses inhibiting Sidman avoidance activity and those causing catalepsy. However, in an extrapyramidal side effect (EPS) test model using haloperidol-sensitized cebus monkeys, 3 elicited signs of EPS at doses approximating those previously determined to be efficacious.

  DOI：

  10.1021/jm00150a011